Itvisma (onasemnogene abeparvovec-brve) Medical Benefit Drug Policy
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy CS2026D0142D alerts
Get alerted when Policy CS2026D0142D changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit prior authorization and coverage of a single lifetime treatment with Itvisma for spinal muscular atrophy in eligible patients, subject to applicable state-specific exceptions.
The concomitant SMN-modifying therapy criterion was revised to remove language stating that current authorizations would be terminated upon Itvisma approval.
Coverage criteria were revised to remove the requirement that current authorizations for concomitant SMN-modifying therapy be terminated upon Itvisma approval.
The supporting References section was updated to reflect current information.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.